SANTA MONICA, Calif., June 15, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today reported financial results for the fiscal third quarter ended April 30, 2017 and provided an update on recent developments and upcoming milestones.
“In the fiscal third quarter, we have made notable progress on our clinical and corporate goals for 2017. On the clinical side, we initiated a Phase 2 clinical trial evaluating our novel, nasally-delivered opioid antagonist candidate, OPNT001, as a potential treatment for Bulimia Nervosa (BN). Additionally, our Alcohol Use Disorder (AUD) program and our pre-clinical work on a heroin vaccine candidate continue to advance. We also gained insight into the effect of two different dosages of nasal naloxone on opioid receptors using positron emission tomography (PET) imaging,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “On the corporate front, we continue to support our NARCAN® Nasal Spray partner, Adapt Pharma Limited, and continue to improve our intellectual property position. In the last nine months, we have also added depth to our management team and have strengthened our corporate governance by appointing a new director to our Board of Directors and by forming committees of our Board of Directors. We remain committed to creating value for our stockholders by working to fulfill our clinical and corporate goals.”
